Last update:

Oncology & Cancer

Real-world data suggests stopping immunotherapy after two years is reasonable in patients with advanced lung cancer

Over the past decade, the approval of immune checkpoint inhibitors has revolutionized treatment for patients with advanced lung cancer, helping many live longer lives and improving overall survival for the disease. However, ...

Medical research

Trial demonstrates one-year progression-free survival in 94% of patients with stage 3 or 4 classic Hodgkin lymphoma

A Phase 3 trial has demonstrated that patients with advanced stage (3 or 4) classic Hodgkin lymphoma who underwent initial treatment with nivolumab, a PD-1 checkpoint inhibitor, and AVD chemotherapy (N-AVD) had a significantly ...

Medical research news

Medical research

Study links post surgery mobility to favorable outcomes

Research led by the Cleveland Clinic in Ohio evaluated postoperative recovery rates from elective surgery in a study, "Association Between Mobilization and Composite Postoperative Complications Following Major Elective Surgery," ...

Oncology & Cancer

Immunotherapy for brain cancer metastases shows clinical benefit

In a phase 2 clinical trial of the immune checkpoint inhibitor pembrolizumab, investigators found that 42 percent of patients with metastatic brain cancer benefited from the therapy, with seven patients in the trial surviving ...

Oncology & Cancer

Memory killer cells can improve survival for melanoma patients

Our skin contains specialized long-lived killer cells that protect against intruders. Researchers at Karolinska Institutet in Sweden have now identified how these cells are formed, and shown that high levels of memory killer ...